These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12789873)

  • 21. Stability evaluation of compounded hydroxyurea 100 mg/mL oral liquids using a novel analytical method involving chemical derivatization.
    Coache D; Friciu M; Bernine Marcellin R; Bonnemain L; Viau A; Roullin VG; Forest JM; Leclair G
    PLoS One; 2022; 17(6):e0270206. PubMed ID: 35749410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability of ganciclovir in extemporaneously compounded oral liquids.
    Anaizi NH; Swenson CF; Dentinger PJ
    Am J Health Syst Pharm; 1999 Sep; 56(17):1738-41. PubMed ID: 10512505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of norfloxacin in an extemporaneously prepared oral liquid.
    Johnson CE; Price J; Hession JM
    Am J Health Syst Pharm; 2001 Apr; 58(7):577-9. PubMed ID: 11296605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes.
    McHenry AR; Wempe MF; Rice PJ
    Int J Pharm Compd; 2017; 21(3):251-254. PubMed ID: 28557788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of extemporaneously compounded temozolomide 10 mg/mL suspensions in Oral Mix SF® in glass and plastic bottles and plastic syringes.
    Lingertat-Walsh K; Weilnau J; Cober MP; Ostrenga A; Poon B; Sales P; Law S; Dupuis LL; Walker SE
    J Oncol Pharm Pract; 2021 Jan; 27(1):78-87. PubMed ID: 32228132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of extemporaneously prepared rifaximin oral suspensions.
    Cober MP; Johnson CE; Lee J; Currie K
    Am J Health Syst Pharm; 2010 Feb; 67(4):287-9. PubMed ID: 20133533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of itraconazole in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; Walters JR
    Am J Health Syst Pharm; 1995 Jan; 52(2):189-91. PubMed ID: 12879547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stability of epinephrine hydrochloride in an extemporaneously compounded topical anesthetic solution of lidocaine, racepinephrine, and tetracaine.
    Larson TA; Uden DL; Schilling CG
    Am J Health Syst Pharm; 1996 Mar; 53(6):659-62. PubMed ID: 8800972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of famotidine in an extemporaneously prepared oral liquid.
    Quercia RA; Jay GT; Fan C; Chow MS
    Am J Hosp Pharm; 1993 Apr; 50(4):691-3. PubMed ID: 8470686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets.
    Jarouche M; Ibrahim M; Pearson J; Low M; Rowe J
    Int J Pharm Compd; 2020; 24(1):77-82. PubMed ID: 32023219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension.
    Cober MP; Johnson CE
    Am J Health Syst Pharm; 2007 Mar; 64(6):644-6. PubMed ID: 17353574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of levofloxacin in an extemporaneously compounded oral liquid.
    VandenBussche HL; Johnson CE; Fontana EM; Meram JM
    Am J Health Syst Pharm; 1999 Nov; 56(22):2316-8. PubMed ID: 10582824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of flucytosine in an extemporaneously compounded oral liquid.
    Wintermeyer SM; Nahata MC
    Am J Health Syst Pharm; 1996 Feb; 53(4):407-9. PubMed ID: 8673661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of dolasetron in two oral liquid vehicles.
    Johnson CE; Wagner DS; Bussard WE
    Am J Health Syst Pharm; 2003 Nov; 60(21):2242-4. PubMed ID: 14619116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4 degrees C.
    Abdel-Rahman SM; Nahata MC
    Am J Health Syst Pharm; 1999 Feb; 56(3):243-5. PubMed ID: 10030510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stability of acetazolamide in suspension compounded from tablets.
    Alexander KS; Haribhakti RP; Parker GA
    Am J Hosp Pharm; 1991 Jun; 48(6):1241-4. PubMed ID: 1858804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of a flavored formulation of acetylcysteine for oral administration.
    Siden R; Johnson CE
    Am J Health Syst Pharm; 2008 Mar; 65(6):558-61. PubMed ID: 18319502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions.
    Caruthers RL; Johnson CE
    Am J Health Syst Pharm; 2007 Jul; 64(14):1513-5. PubMed ID: 17617502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulation and stability of an extemporaneously compounded oral solution of chlorpromazine HCl.
    Prohotsky DL; Juba KM; Zhao F
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):367-70. PubMed ID: 25338106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability of flecainide acetate in an extemporaneously compounded oral suspension.
    Wiest DB; Garner SS; Pagacz LR; Zeigler V
    Am J Hosp Pharm; 1992 Jun; 49(6):1467-70. PubMed ID: 1529992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.